Acute Lymphoblastic Leukaemias (ALL) Unknown Status Phase 1 / 2 Trials for Alemtuzumab (DB00087)

Also known as: Acute Lymphoblastic Leukemias / Acute Leukemia, Lymphoblastic / Acute Lymphoblastic Leukaemia / Acute Lymphoblastic Leukemia / Leukemia, Lymphoblastic, Acute / Lymphoblastic Leukemia, Acute / Leukemia, Acute Lymphoblastic / Leukaemia, Lymphoblastic, Acute / Acute Lymphoblastic Leukemia (ALL) / Leukemia, Lymphoblastic,Acute / Acute Leukaemia, Lymphoblastic / Acute lymphoblastic leukemia with failed remission / Leukemia lymphoblastic acute / Lymphoid leukaemia, acute / Acute lymphoid leukaemia / Lymphoid leukemia, acute / Acute lymphoid leukemia / ALL / Leukaemia lymphoblastic acute / Acute lymphocytic leukemia / Acute lymphatic leukaemia / Leukaemias acute lymphocytic / Acute lymphatic leukemia / Acute lymphocytic leukaemia

IndicationStatusPhase
DBCOND0073466 (Acute Lymphoblastic Leukaemias (ALL))Unknown Status1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00983528Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic LeukemiaTreatment